hlg-20230630

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 001-40209

Heliogen, Inc.

(Exact name of registrant as specified in its charter)


Delaware			85-4204953
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
130 West Union Street, Pasadena, California			91103
(Address of Principal Executive Offices)			(Zip Code)

Registrant's telephone number, including area code: (626) 720-4530

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.0001 par value per share

HLGN

New York Stock Exchange

Warrants, each whole warrant exercisable for shares of Common stock at an exercise price of $11.50 per share

HLGN.W

New York Stock Exchange

Preferred Share Purchase Rights

N/A

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

As of August 3, 2023, the registrant had 205,096,999 shares of common stock, par value $0.0001 per share outstanding.

Table of Contents


			Page
Cautionary Note Regarding Forward-Looking Statements			3
Part I - Financial Information
Item 1. Financial Statements
Consolidated Balance Sheets			5
Consolidated Statements of Operations			6
Consolidated Statements of Comprehensive Loss			7
Consolidated Statements of Shareholders’ Equity			8
Consolidated Statements of Cash Flows			10
Notes to Unaudited Consolidated Financial Statements			12
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations			25
Item 3. Quantitative and Qualitative Disclosures About Market Risk			31
Item 4. Controls and Procedures			32
Part II - Other Information
Item 1. Legal Proceedings			33
Item 1A. Risk Factors			33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			33
Item 3. Defaults Upon Senior Securities			33
Item 4. Mine Safety Disclosures			33
Item 5. Other Information			33
Item 6. Exhibits			34
Signatures			35

Table of Contents

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. All statements, other than statements of present or historical fact included in this Quarterly Report regarding our future financial performance, as well as our strategy, future operations, financial position, estimated revenues, losses, projected costs, prospects, plans and objectives of management are forward-looking statements. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative of such terms or other similar expressions. These forward-looking statements are based on management’s current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. Although we believe such expectations and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond our control. In addition, management’s assumptions about future events may prove to be inaccurate. All readers are cautioned that the forward-looking statements contained in this Quarterly Report are not guarantees of future performance and we cannot assure any reader that such statements will be realized or that the forward-looking events and circumstances will occur.

As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:

•our financial and business performance, including risk of uncertainty in our financial projections and business metrics and any underlying assumptions thereunder;

•changes in our business and strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans;

•our ability to execute our business model, including market acceptance of our planned products and services and achieving sufficient production volumes at acceptable quality levels and prices;

•our ability to maintain our listing on the New York Stock Exchange (“NYSE”);

•changes in domestic and foreign business, market, financial, political, legal conditions and applicable laws and regulations;

•our ability to grow market share in our existing markets or new markets we may enter;

•our ability to achieve and maintain profitability in the future;

•our ability to access sources of capital to finance operations, growth and future capital requirements;

•our ability to maintain and enhance our products and brand, and to attract and retain customers;

•our ability to find new partners for product offerings;

•the success of strategic relationships with third parties;

•our ability to scale in a cost-effective manner;

•developments and projections relating to our competitors and industry;

•supply chain disruptions;

•our ability to protect our intellectual property (“IP”);

•the actions of stockholders and the related impact on the price of our common stock;

Table of Contents

•expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended;

•our ability to find and retain critical employee talent and key personnel;

•our ability to successfully manage the transition process to a new executive team;

•the possibility that we may be adversely impacted by other economic, business, and/or competitive factors;

•future exchange and interest rates;

•the outcome of any known and unknown litigation and regulatory proceedings; and

•other risks and uncertainties, including those disclosed under “Item 1A. Risk Factors” contained in Part I of our Annual Report on Form 10-K for the year ended December 31, 2022 (our “Annual Report”) filed with the Securities and Exchange Commission (“SEC”) on March 29, 2023, as supplemented by the risk factor previously disclosed in Part II, Item 1A. Risk Factors in our Quarterly Report for the period ended March 31, 2023, and the risk factors and other cautionary statements contained in other filings that have been made or will be made with the SEC by the Company.

Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Should one or more of the risks or uncertainties described in this Quarterly Report, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Our SEC filings are available publicly on the SEC’s website at www.sec.gov.

You should read this Quarterly Report with the understanding that our actual future results, levels of activity and performance as well as other events and circumstances may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

Table of Contents

Part I - Financial Information

Item 1. Financial Statements

Heliogen, Inc.

Consolidated Balance Sheets

($ in thousands, except share data)

(Unaudited)


	June 30, 2023		December 31, 2022
ASSETS
Cash and cash equivalents	$	43,498	$	45,719
Short-term restricted cash	—		655
Investments	64,309		97,504

Receivables	5,820		9,195
Inventories	4,304		2,442
Prepaid and other current assets	4,518		3,306
Total current assets	122,449		158,821
Operating lease right-of-use assets	14,132		14,772
Property, plant and equipment, net	6,426		7,071
Goodwill and intangible assets, net	113		1,160
Long-term restricted cash	1,500		1,500
Collaboration Warrants, non-current	4,292		5,282
Other long-term assets	5,006		3,013
Total assets	$	153,918	$	191,619
LIABILITIES AND SHAREHOLDERS’ EQUITY
Trade payables	$	845	$	6,921
Contract liabilities	12,247		10,348
Contract loss provisions	27,500		28,418

Accrued expenses and other current liabilities	9,784		5,602
Total current liabilities	50,376		51,289


Operating lease liabilities, non-current	13,158		13,921
Warrant liabilities	391		642
Other long-term liabilities	1,673		443
Total liabilities	65,598		66,295
Commitments and contingencies (Note 15)

Shareholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares outstanding as of June 30, 2023 and December 31, 2022	—		—
Common stock, $0.0001 par value; 500,000,000 shares authorized and 204,585,176 shares issued and outstanding (excluding restricted shares of 40,893) as of June 30, 2023; 192,924,429 shares issued and outstanding (excluding restricted shares of 59,770) as of December 31, 2022	20		19
Additional paid-in capital	429,563		434,478
Accumulated other comprehensive loss	(456)		(593)
Accumulated deficit	(340,807)		(308,580)
Total shareholders’ equity	88,320		125,324
Total liabilities and shareholders’ equity	$	153,918	$	191,619

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Operations

($ in thousands, except per share and share data)

(Unaudited)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Revenue:
Services revenue	$	912	$	964	$	1,778	$	3,008
Grant revenue	482		1,428		1,553		2,923
Total revenue	1,394		2,392		3,331		5,931
Cost of revenue:
Cost of services revenue (including depreciation)	1,060		1,386		2,001		3,978
Cost of grant revenue	442		1,428		1,513		2,923

Provision for contract losses	20		—		390		33,737
Total cost of revenue	1,522		2,814		3,904		40,638
Gross loss	(128)		(422)		(573)		(34,707)

Operating expenses:
Selling, general and administrative	17,652		22,403		21,817		42,465
Research and development	4,946		5,905		10,206		15,280


Impairment charges	—		—		1,008		—
Total operating expenses	22,598		28,308		33,031		57,745
Operating loss	(22,726)		(28,730)		(33,604)		(92,452)

Interest income, net	270		213		553		407

Gain (loss) on warrant remeasurement	(52)		8,284		252		12,310
Other income (expense), net	827		(109)		574		(185)
Net loss before taxes	(21,681)		(20,342)		(32,225)		(79,920)
(Provision) benefit for income taxes	(2)		125		(2)		735
Net loss	$	(21,683)	$	(20,217)	$	(32,227)	$	(79,185)





Loss per share:
Loss per share – Basic and Diluted	$	(0.11)	$	(0.11)	$	(0.16)	$	(0.42)
Weighted average number of shares outstanding – Basic and Diluted	200,616,841		190,182,474		198,768,335		187,123,737

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Comprehensive Loss

($ in thousands)

(Unaudited)


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
Net loss	$	(21,683)	$	(20,217)	$	(32,227)	$	(79,185)
Other comprehensive income (loss), net of taxes:
Unrealized gains (losses) on available-for-sale securities	25		(127)		198		(506)
Cumulative translation adjustment	(24)		(323)		(61)		(324)
Total other comprehensive income (loss), net of taxes	1		(450)		137		(830)
Comprehensive loss	$	(21,682)	$	(20,667)	$	(32,090)	$	(80,015)

The accompanying notes are an integral part of these unaudited consolidated financial statements.

Table of Contents

Heliogen, Inc.

Consolidated Statements of Shareholders’ Equity

($ in thousands, except share data)

(Unaudited)


		Three Months Ended June 30, 2023
	Common Stock		Additional Paid-in Capital			Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total
		Shares			Amount
Balance as of March 31, 2023		195,732,947	$	19		$	425,590	$	(457)	$	(319,124)	$	106,028
Net loss		—	—			—		—		(21,683)		(21,683)
Other comprehensive loss		—	—

SEC Form 10-Q filed by Heliogen Inc.